Navigation Links
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Date:1/23/2008

- Second filing provides opportunity for additional indications and

increased potential market -

PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine (MSI-1436) in type 2 diabetes is now in effect. This application represents the second IND filed by the Company in 2007 for MSI- 1436. A previous IND for the treatment of obesity, under which Genaera is currently conducting phase 1 clinical trials, has been in effect since April 2007. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.

"A growing body of data indicates that inhibition of PTP-1B is central to controlling the key pathologies associated with type 2 diabetes; namely insulin sensitivity and obesity," said Jack Armstrong, President and Chief Executive Officer of Genaera. "Since MSI-1436 has demonstrated significant potential to impact both the insulin and leptin pathways, we believe this new IND provides us with the opportunity for additional indications and a much broader potential market. Therefore, we are implementing a clinical plan which evaluates the drug's potential in type 2 diabetes, in addition to our ongoing obesity studies. With this dual strategy, we believe that we are well-positioned to maximize the therapeutic potential of MSI-1436."

In October 2007, Genaera completed the first phase 1 study of MSI-1436 in healthy obese and overweight subjects. MSI-1436 is currently being evaluated in a second pha
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Long-acting insulin is safer and more effective than ... according to new research published in the ... and twice-daily doses of both long- and intermediate-acting ... , "In patients with Type 1 diabetes, we ... insulin when it came to controlling blood sugar, ...
(Date:10/1/2014)... holiday gift ideas? Éminence Organic Skin Care, the leader in ... season. Starting October 1st 2014, new spa gift sets are ... from two luxury skin care gift sets made from the ... to deliver whole body beauty. , The luxurious Body ... formulated to suit all skin types and will tick all ...
(Date:10/1/2014)... To help raise awareness about women’s health, leading Detroit ... several tips for women looking to live a healthier and ... should start each day with meditation, prayer and breathing exercises. ... yourself for the rest of the day and prevent the ... and fitness tips include:, -Drink half your weight in ounces ...
(Date:9/30/2014)... proactive about potential disease outbreaks like Ebola and establish ... Editorial in the October issue of Australian and ... from Monash University and Heath Kelly from the Australian ... , "Australia would do well to heed the lessons ... a consistent and outward looking response," the authors said. ...
(Date:9/30/2014)... conceived either less than one year or more than five ... increased risk for autism, a new study suggests. However, ... that the research can,t prove that birth spacing has any ... that parents understand that the odds for autism are still ... apart," said outside expert Dr. Andrew Adesman. He is chief ...
Breaking Medicine News(10 mins):Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2
... food to infants less than six months old is not ... allergies later and new moms should rather breastfeed them exclusively, ... avoided for the first six months, and certain items like ... until even later, according to the American College of Allergy, ...
... Consuming naturally occurring compounds in cocoa could improve ... also help blood flow// in menopausal women with ... and gives us new insights into how cocoa ... ways not previously known,' said Harold Schmitz, PhD, ...
... embryo formation has been discovered in malignant melanoma cells ... Scientist discovered this protein called Nodal by injecting malignant ... were able to induce abnormal embryonic skull and backbone ... published in online issue of the journal, Nature Medicine. ...
... the researchers at the University of Florida, Gainesville, mice based ... treat hereditary diseases of the heart.// , This ... with muscular dystrophy that damages the heart. The findings, published ... the way for studies in humans that could begin as ...
... Health service helpline NHS 24 has been criticized severely because a ... old lady.// ,Retired nurse Mary Smith, 87 had an ... helpline twice but the nurse curtly replied that she could not ... for a GP to attend to her. Then when the GP ...
... Hyderabad-based Aurobindo Pharma Ltd today said it has ... fixed drug combination product used for anti-HIV treatment. ... contains Lamivudine 150mg+2idovudine300mg tablets co-packaged with Abacavir 300mg ... ,This combination pack enhances convenience, is cost-effective ...
Cached Medicine News:Health News:Protein Involved In Embryo Formation Found In Malignant Cells 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: